Blood cancers, Cell type, Lymphoma, Secondary cancers
Results
Phase 2
This trial looked at adding ibrutinib to rituximab to treat post-transplant lymphoproliferative disorder. Post-transplant lymphoproliferative disorder can develop after:
a . This is a treatment for some types of cancer.
an organ transplant such as the heart, lung or liver
The trial was open for people to join between 2017 and 2020. The team published the results in 2024.
Recruitment start: 13 January 2017
Recruitment end: 17 March 2020
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Tobias Menne
Bloodwise
Janssen
University of Birmingham
Last reviewed: 2 July 2025
CRUK internal database number: 15564
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
